Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2

ACS Chem Neurosci. 2020 Feb 19;11(4):592-603. doi: 10.1021/acschemneuro.9b00618. Epub 2020 Feb 4.

Abstract

Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new 18F-labeled SV2A PET imaging probe, [18F]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.

Keywords: Alzheimer’s disease; PET; Parkinson’s disease; SV2A; fluorine-18; non-human primate.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology*
  • Animals
  • Brain / metabolism
  • Brain / pathology
  • Epilepsy / diagnosis
  • Epilepsy / pathology*
  • Humans
  • Membrane Glycoproteins / metabolism*
  • Nerve Tissue Proteins / metabolism
  • Primates / metabolism
  • Synaptic Vesicles / metabolism
  • Synaptic Vesicles / pathology*

Substances

  • Membrane Glycoproteins
  • Nerve Tissue Proteins